Table 1.
Clinical Characteristics of Study Patients
| All patients | GIB | No GIB | p-value | |
|---|---|---|---|---|
| n=154 | n=29 | n=125 | ||
| Age (± SEM) | 55.4±0.87 years | 61.2±1.5 | 54.1±1.1 | 0.0003 |
| Gender | 122 M/ 32 F | 26 M/ 3 F | 96 M/29 F | |
| Etiology of CHF | NS | |||
| Ischemic | 89 (57%) | 16 (55%) | 73 (57%) | |
| Nonischemic | 65(43%) | 13 (45%) | 52 (43%) | |
| Therapy type | 0.015 | |||
| Bridge to transplant | 105 (68%) | 14 (48%) | 91 (73%) | |
| Destination therapy | 49 (32%) | 15 (52%) | 34 (27%) | |
| Prior GIB | 5 (3%) | 2 (7%) | 3 (2%) | NS |
| Prior anticoagulation | 93 (60%) | 23 (79%) | 69 (56%) | 0.02 |
| Antithrombotic therapy | ||||
| Warfarin | 111 (72.1%) | 20 (69%) | 91 (72.8%) | NS |
| Aspirin | 143 (92.9%) | 28 (97%) | 115 (92.0%) | NS |
| Clopidogrel | 5 (3%) | 1 (3%) | 4 (3%) | NS |
| Dipyridamole | 11 (7.7%) | 2 (6.9%) | 9 (7.2%) | NS |
| PPI use | 113 (73%) | 23 (79%) | 90(73%) | NS |
| Mortality | 55 (35%) | 10 (34%) | 45 (35%) | NS |
GIB: gastrointestinal bleeding; PPI: proton pump inhibitor